- Home
- AMBO vs ENVB Comparison
AMBO vs ENVB Comparison
Compare AMBO & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- ENVB
- Stock Information
- Founded
- AMBO 2000
- ENVB 1994
- Country
- AMBO United States
- ENVB United States
- Employees
- AMBO N/A
- ENVB N/A
- Industry
- AMBO Other Consumer Services
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- ENVB Health Care
- Exchange
- AMBO Nasdaq
- ENVB Nasdaq
- Market Cap
- AMBO 5.1M
- ENVB 4.2M
- IPO Year
- AMBO 2010
- ENVB N/A
- Fundamental
- Price
- AMBO $1.42
- ENVB $0.31
- Analyst Decision
- AMBO
- ENVB Strong Buy
- Analyst Count
- AMBO 0
- ENVB 1
- Target Price
- AMBO N/A
- ENVB $10.00
- AVG Volume (30 Days)
- AMBO 157.1K
- ENVB 161.8K
- Earning Date
- AMBO 12-27-2024
- ENVB 11-14-2024
- Dividend Yield
- AMBO N/A
- ENVB N/A
- EPS Growth
- AMBO N/A
- ENVB N/A
- EPS
- AMBO N/A
- ENVB N/A
- Revenue
- AMBO $9,163,000.00
- ENVB N/A
- Revenue This Year
- AMBO N/A
- ENVB N/A
- Revenue Next Year
- AMBO N/A
- ENVB N/A
- P/E Ratio
- AMBO N/A
- ENVB N/A
- Revenue Growth
- AMBO N/A
- ENVB N/A
- 52 Week Low
- AMBO $1.00
- ENVB $0.30
- 52 Week High
- AMBO $6.30
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- AMBO 40.93
- ENVB 35.74
- Support Level
- AMBO $1.35
- ENVB $0.31
- Resistance Level
- AMBO $1.56
- ENVB $0.37
- Average True Range (ATR)
- AMBO 0.18
- ENVB 0.03
- MACD
- AMBO -0.05
- ENVB 0.00
- Stochastic Oscillator
- AMBO 7.55
- ENVB 17.46
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.